<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02054559</url>
  </required_header>
  <id_info>
    <org_study_id>AMC_NHL02</org_study_id>
    <nct_id>NCT02054559</nct_id>
  </id_info>
  <brief_title>R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL</brief_title>
  <acronym>ASPIRE</acronym>
  <official_title>Randomized Phase III Trial Comparing R-CHOP Alone and R-CHOP Plus Radiotherapy for Localized CD20+ Diffuse Large B-cell Lymphoma (DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety of chemotherapy alone and combined modality therapy in the&#xD;
      treatment of localized CD20 (+) diffuse large B-cell lymphoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No consensus among trial centers regarding protocol&#xD;
  </why_stopped>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare 3-year event-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>definition of events: failure to achieve CR after completion of planned 1st-line treatment, progression of disease, relapse, institution of a new anticancer treatment or any cause of death) rate in patients with CD20 (+) diffuse large B-cell lymphoma treated with either R-CHOP chemotherapy alone or R-CHOP plus radiotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate and compare OS between the two arms</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate and compare the ORR and CR rate</measure>
    <time_frame>after completion of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate and compare disease-free survival (DFS)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate treatment-failure pattern</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events in each arm</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess patient-reported outcomes (PROs) in both arms</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A role of interim PET after 3 cycles of R-CHOP chemotherapy: correlation with PFS and OS</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Total 6 cycles of R-CHOP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Total 3 cycles of R-CHOP + RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total 3 cycles of R-CHOP followed by radiotherapy (involved field or involved site radiotherapy, 30-50 Gy/ 15-25 fractions)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CHOP</intervention_name>
    <description>R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (or prednisolone))</description>
    <arm_group_label>Total 3 cycles of R-CHOP + RT</arm_group_label>
    <arm_group_label>Total 6 cycles of R-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <arm_group_label>Total 3 cycles of R-CHOP + RT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Histologically confirmed CD20-positive Diffuse Large B-cell Lymphoma (DLBCL), NOS&#xD;
&#xD;
          -  Immunostains for CD20, CD5, CD3, CD10, MUM-1, BCL-6, BCL-2 and Ki-67 and the in situ&#xD;
             hybridization for Epstein-Barr virus are recommended for diagnosis of DLBCL, NOS.&#xD;
&#xD;
          -  No prior treatment for DLBCL&#xD;
&#xD;
          -  Stage I or contiguous II disease (Involvement of two adjacent lymph node regions or&#xD;
             organ involvement with regional lymph nodes)&#xD;
&#xD;
          -  Performance status: ECOG 0-2.&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Cardiac ejection fraction ≥ 45% as measured by MUGA or 2D ECHO without clinically&#xD;
             significant abnormalities&#xD;
&#xD;
          -  Adequate renal function: serum creatinine level &lt; 2 mg/dL&#xD;
&#xD;
          -  Adequate liver functions&#xD;
&#xD;
          -  Adequate hematological function: hemoglobin ≥ 9.0 g/dL absolute neutrophil count (ANC)&#xD;
             ≥ 1,500/μL and platelet count ≥ 75,000/μL, unless abnormalities are due to bone marrow&#xD;
             involvement by lymphoma&#xD;
&#xD;
          -  Life expectancy &gt;= 6 months&#xD;
&#xD;
          -  A negative serum or urine pregnancy test prior to treatment must be available both for&#xD;
             pre menopausal women and for women who are &lt; 1 years after the onset of menopause.&#xD;
&#xD;
          -  Female patients of child bearing potential must use an effective method of birth&#xD;
             control (i.e. hormonal contraceptive, intrauterine device,diaphragm with spermicide,&#xD;
             condom with spermicide or abstinence) during treatment period and 1 month thereafter;&#xD;
             Males must use an effective method of birth control during treatment period and 3&#xD;
             months thereafter.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other subtypes NHL than CD20 (+) DLBCL, NOS&#xD;
&#xD;
          -  Transformed DLBCL from follicular lymphoma or other indolent lymphomas&#xD;
&#xD;
          -  Bulky disease ( longest diameter &gt;=10 cm)&#xD;
&#xD;
          -  Previous treatment for DLBCL with immunotherapy or chemotherapy except for short-term&#xD;
             corticosteroids (duration of ≤ 8 days) before inclusion&#xD;
&#xD;
          -  CNS involvement by lymphoma or any evidence of spinal cord compression.&#xD;
&#xD;
          -  Primary Central Nervous System (CNS) DLBCL&#xD;
&#xD;
          -  Primary testicular lymphoma&#xD;
&#xD;
          -  Primary breast lymphoma&#xD;
&#xD;
          -  Patients with a known history of HIV seropositivity or HCV (+). (Patients who have HBV&#xD;
             (+) are eligible. However, primary prophylaxis using antiviral agents (i.e.&#xD;
             lamivudine, etc) is recommended for HBV carrier to prevent HBV reactivation during&#xD;
             whole treatment period.)&#xD;
&#xD;
          -  Prior history of malignancies other than lymphoma (except for basal cell or squamous&#xD;
             cell carcinoma of the skin, early gastric cancer or carcinoma in situ of the cervix or&#xD;
             breast or untreated prostatic cancer without any plan for a treatment) unless the&#xD;
             patient has been free of the disease for ≥ 3 years&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Men who are not surgically sterile and women of childbearing potential not employing&#xD;
             adequate contraception&#xD;
&#xD;
          -  Other serious illness or medical conditions&#xD;
&#xD;
          -  Unstable cardiac disease despite treatment, myocardial infarction within 6 months&#xD;
             prior to study entry&#xD;
&#xD;
          -  History of significant neurological or psychiatric disorders including dementia or&#xD;
             seizures&#xD;
&#xD;
          -  Active uncontrolled infection (viral, bacterial or fungal infection)&#xD;
&#xD;
          -  Other serious medical illnesses&#xD;
&#xD;
          -  Known hypersensitivity to any of the study drugs or its ingredients&#xD;
&#xD;
          -  Concomitant administration of any other experimental drug under investigation, or&#xD;
             concomitant chemotherapy, hormonal therapy, or immunotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>January 29, 2014</study_first_submitted>
  <study_first_submitted_qc>February 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2014</study_first_posted>
  <last_update_submitted>February 20, 2016</last_update_submitted>
  <last_update_submitted_qc>February 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Cheolwon Suh</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>localized</keyword>
  <keyword>diffuse large B-cell lymphoma</keyword>
  <keyword>R-CHOP chemotherapy</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

